M Anastasiou,A Kyriazoglou,I Kotsantis et al.
M Anastasiou et al.
Sarcomas are tumors that originate from mesenchymal cells. The variety of sarcomas' response to chemotherapy and the wide range of prognosis reflect their heterogeneity. In order to improve the rates of response, the research has been orien...
Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma [0.03%]
人多能干细胞来源的嵌合抗原受体巨噬细胞在胶质母细胞瘤中的应用研究
G Jin,Y Chang,X Bao
G Jin
Background: Glioblastoma (GBM) is an aggressive brain tumor giving a poor prognosis with the current treatment options. The advent of chimeric antigen receptor (CAR) T-cell therapy revolutionized the field of immunotherap...
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors [0.03%]
PD-1和PD-L1基因单核苷酸变异体在预测晚期黑色素瘤患者接受PD-1抑制剂治疗的预后和疗效中的作用
A Boutros,R Carosio,D Campanella et al.
A Boutros et al.
Background: Despite having revolutionized the treatment paradigm for advanced melanoma, not all patients benefit from immune checkpoint inhibitor therapy. To date, there are no predictive biomarkers for response or the oc...
Corrigendum to "Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies": [Immuno-Oncology and Technology 10 (2023) 100394] [0.03%]
“利用理性工程改进腺苷脱氨酶2酶以增强T细胞治疗的效力”的勘误：[免疫肿瘤学和技术 10(2023) 100394]
J R Cox,M Jennings,C Lenahan et al.
J R Cox et al.
[This corrects the article DOI: 10.1016/j.iotech.2023.100394.]. © 2023 European Society for Medical Oncology. Published by Elsevier Ltd. All rights rese...
Published Erratum
Immuno-oncology technology. 2023 Oct 17:20:100410. DOI:10.1016/j.iotech.2023.100410 2023
CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy [0.03%]
2023年国际免疫治疗大会（CIMT）会议纪要——第20届癌症免疫治疗协会年度会议
J Dallmann,J Freitag,C Jung et al.
J Dallmann et al.
The Association for Cancer Immunotherapy (CIMT) celebrated the 20th anniversary of the CIMT Annual Meeting. CIMT2023 was held 3-5 May 2023 in Mainz, Germany. 1051 academic and clinical professionals from over 30 countries attended the meeti...
Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma [0.03%]
基于检点抑制剂治疗临床反应的晚期黑色素瘤外周免疫细胞监督分类聚集研究
A H Kverneland,S U Thorsen,J S Granhøj et al.
A H Kverneland et al.
Background and purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no b...
Y Wang,H Wang
Y Wang
Immunotherapy that aims to boost the body's immune responses against pathogens or diseased cells has achieved significant progress for treating different diseases over the past several decades, especially with the success of checkpoint bloc...
Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies [0.03%]
改进型腺苷脱氨酶2的理性工程以增强T细胞疗法的效果
J R Cox,M Jennings,C Lenahan et al.
J R Cox et al.
Adenosine is a potent immunosuppressive metabolite that accumulates in the extracellular space within solid tumors and inhibits the antitumor function of native immune cell responses as well as chimeric antigen receptor (CAR) T-cell therapi...
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors [0.03%]
工程化嵌合抗原受体T细胞治疗实体瘤的研究
A Neeser,R Ramasubramanian,C Wang et al.
A Neeser et al.
The early clinical success and subsequent US Food and Drug Administration approval of chimeric antigen receptor (CAR)-T cell therapy for leukemia and lymphoma affirm that engineered T cells can be a powerful treatment for hematologic malign...
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond [0.03%]
着眼黑色素瘤免疫治疗：Tebentafusp及其后疗法
C Gerard,B Shum,P Nathan et al.
C Gerard et al.
Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoin...